Milliken & Company Marks Five Years of Progress in 2022 Sustainability Report, “FOR HUMANKIND”
Diversified global manufacturer Milliken & Company released its fifth annual sustainability report, “For HumanKind,” today. The report tracks Milliken’s progress on its 2025 Sustainability Goals, originally set in 2019, and provides initial baseline data for its net-zero targets, formally verified in 2022. The report showcases how sustainability impacts Milliken’s business today and is integral to the company’s future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005301/en/
Milliken's sustainability report, entitled "For HumanKind," shares five years of progress on the company's sustainability goals. (Photo: Business Wire)
Milliken’s announcement of its short- and long-term targets to reach net-zero by 2050 added a new dimension to its sustainability effort. Milliken is one of the first 50 companies in the world, and the first in South Carolina, to have science-based targets approved by the U.N.- backed Science Based Targets initiative (SBTi). These targets joined 12 other sustainability goals Milliken set forth to guide its work with its people, its products and the planet through the lens of human benefit and science.
“It’s been inspiring to see what we’ve accomplished in just a few years. We know we can continue this progress as we rally our associates, our shareholders, our partners, and our customers to be a part of the solution to the world’s most pressing challenges, including climate change,” says Milliken President and CEO Halsey Cook. “Our work is far from over, and we know that teamwork is the key to accelerating the innovation that will unlock success–not only for ourselves, but for all of humankind.”
Also in 2022, Milliken announced it would phase out the use of PFAS in its fibers and finishes within its textile portfolio, completing this exit in December 2022. In line with its commitment to end-of-life solutions for plastics, Milliken’s corporate foundation—the Milliken & Company Charitable Foundation—invested in The Recycling Partnership’s Center for Sustainable Behavior and Impact, which offers tangible solutions for increasing recycling rates in U.S. households. Diversity among Milliken’s U.S. management team is up 10% since 2018, representing 36% gender diversity and 17% racial/ethnic diversity. Notably, Milliken also met its goal for a 25% reduction in indexed greenhouse gas emissions in its operations this year and will now focus on greater GHG emission reductions in line with its net-zero targets.
“Our sustainability efforts continue to evolve, as the shift from our greenhouse gas emissions goal to the more holistic net-zero targets shows,” adds Milliken SVP and General Counsel Kasel Knight. “We’re proud of what we accomplished in 2022, and we’re confident that we’ll improve our efforts with new opportunities to live our purpose of positively impacting the world for generations to come.”
Milliken’s 2022 Sustainability Report can be found at milliken.com/sustainability, alongside additional net-zero resources and prior years’ reports.
About Milliken
Milliken & Company is a global manufacturing leader whose focus on materials science delivers tomorrow’s breakthroughs today. From industry-leading molecules to sustainable innovations, Milliken creates products that enhance people’s lives and deliver solutions for its customers and communities. Drawing on thousands of patents and a portfolio with applications across the textile, specialty chemical, flooring and healthcare businesses, the company harnesses a shared sense of integrity and excellence to positively impact the world for generations. Discover more about Milliken’s curious minds and inspired solutions at milliken.com and on Facebook, Instagram, and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005301/en/
Contact information
Betsy Sikma
betsy.sikma@milliken.com
864.909.7908
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BYD Unleashes FANG CHENG BAO, A New Brand that Specializes in Professional and Personalized Identities9.6.2023 06:41:00 EEST | Press release
On June 9, BYD, the world’s leading manufacturer of new energy vehicles, officially announced its new sub-brand FANG CHENG BAO. The brand, as the fifth in the row of the BYD brand matrix, will meet the increasingly personalized needs of consumers by offering a series of unique and professional-grade new energy vehicle models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005841/en/ SF (Photo: Business Wire) FANG CHENG BAO is a significant addition to BYD’s diversified brand matrix, following its Dynasty series, Ocean series, Denza, and Yangwang. The vehicle lineup of FANG CHENG BAO ranges from off-road vehicles to sports cars, and its initial model, a hardcore SUV codenamed SF, is expected to launch this year. The brand name FANG CHENG BAO translates literally as “Formula” and “Leopard” from Chinese, symbolizing the pursuit of the transformative rise and the exploration of digital realms. It blends the standards and r
FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia9.6.2023 02:40:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Applications (BLAs) for the investigational treatment exagamglogene autotemcel (exa-cel) for severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). The FDA has granted Priority Review for SCD and Standard Review for TDT and assigned Prescription Drug User Fee Act (PDUFA) target action dates of December 8, 2023, and March 30, 2024, respectively. Updated data from the pivotal trials supporting the regulatory submissions will be presented at the Annual European Hematology Association Congress on June 11, 2023. “We are very pleased with the acceptance of the submissions and the Priority Review designation for SCD by the FDA, as well as the progress of the exa-cel filings in the EU and U.K.,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Exa-
Citi Global Wealth Investments Issues Mid-Year Wealth Outlook 2023 - Opportunities on the Horizon: Investing Through a Slowing Economy9.6.2023 00:59:00 EEST | Press release
Citi Global Wealth Investments today released its Mid-Year Wealth Outlook 2023 report - Opportunities on the Horizon: Investing Through a Slowing Economy. This biannual report sets out Citi Global Wealth’s outlook on how investors should approach developments in the global economy, markets and geopolitics. Though 2023 has been full of extraordinary events, Citi Global Wealth sees the remainder of the year as an opportunity. We are in a “rolling recession” where parts of the US economy are growing even as others contract. As inflation slowly eases following a period of rapid Fed rate hikes, the group believes that keeping portfolios invested is imperative. While the current asset allocation strategy remains defensive, Citi Global Wealth see numerous opportunities to adjust their portfolios over time, as the Fed shifts from interest rate hikes to cuts. We believe that current markets will lead into a meaningful potential recovery in 2024. “Though the broader bear market is not yet over,
Verisign Reports Internet Has 354.0 Million Domain Name Registrations at the End of the First Quarter of 20238.6.2023 23:55:00 EEST | Press release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the first quarter of 2023 closed with 354.0 million domain name registrations across all top-level domains (TLDs), an increase of 3.5 million domain name registrations, or 1.0%, compared to the fourth quarter of 2022.1,2 Domain name registrations also increased by 3.5 million, or 1.0%, year over year.1,2 The .com and .net TLDs had a combined total of 174.8 million domain name registrations in the domain name base3 at the end of the first quarter of 2023, an increase of 1.0 million domain name registrations, or 0.6%, compared to the fourth quarter of 2022. The .com and .net TLDs had a combined increase of 0.1 million domain name registrations, or 0.1%, year over year. As of March 31, 2023, the .com domain name base totaled 161.6 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations. New .com and .net
Momcozy Introduces the Revolutionary M5 All-in-one Hands-free Breast Pump - Empowering Busy Moms with the Ultimate Maternity Solution8.6.2023 23:00:00 EEST | Press release
Momcozy, the esteemed maternity and baby brand favored by over two million moms worldwide, proudly unveils the revolutionary M5 all-in-one hands-free breast pump. Designed to provide the ultimate pumping experience for busy breastfeeding moms, this cutting-edge device showcases Momcozy's commitment to meeting the needs of mothers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230608005079/en/ M5 All-in-one Handsfree Breast Pump (Graphic: Business Wire) Renowned for its position as a leader in the North American electric breast pump market, Momcozy distinguishes itself yet again with the M5 all-in-one hands-free breast pump. Driven by a user research team that believes in "cozy designs born from love" and strives to cater to customer needs, Momcozy has conducted extensive interviews with thousands of mothers over the past two years. The team's latest findings highlight "comfort" as the most frequently mentioned req
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom